This article is more than 5 years old. Information may no longer be current.

Envisia initiates phase 2a clinical trial for glaucoma treatment

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Envisia Therapeutics initiated a phase 2a clinical trial to investigate the safety and tolerability of ENV515 in glaucoma patients, according to a press release.

ENV515 is a biodegradable particle replication in non-wetting templates (PRINT) formulation of travoprost and may reduce IOP for up to 6 months, the release said.

The open-label clinical trial will enroll 20 glaucoma patients in the U.S. Results are expected by mid-year, the release said.